7 news items
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. For additional
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
a decentralized CAR-T manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders
Galapagos creates new subscription right plans
GLPG
16 May 24
RMV," intended for the employees of its French subsidiary, Galapagos SASU, and "Subscription Right Plan 2024 ROW", primarily intended
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
GLPG
15 May 24
results for our patients, employees and shareholders. For additional information, please
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
, employees, and shareholders. For additional information, please
miy2mipvy l79nbcrlg
GLPG
4 Apr 24
, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. For additional information, please
bgrfu fktaqbc82uoe3ob8vb79k1x1hbnqyg84
GLPG
26 Mar 24
, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. For additional information, please
- Prev
- 1
- Next